Spherix Executes Machine Learning Scientific Research Agreement

As with many cancers, early detection is vital, but in pancreatic cancer, surgical intervention is currently the only effective treatment for the extension of life. Unfortunately, only 20% of individuals are diagnosed with pancreatic cancer early enough to be surgical candidates. Reliable markers for early detection will expand the number of patients who are eligible for life-extending surgery.

The goal of the machine learning is to develop panels of markers to rapidly identify patients who have initiated early events in pancreatic cancer. Moreover, it is the goal of the machine learning protocols to identify which individuals are at risk for slow or rapid progression of the disease and catalyze the development of better early detection methods. Finally, Spherix management hopes that the machine learning approach will help identify drugs best suited for individual patient treatment.

We believe machine learning and artificial intelligence will be an important part of the future of oncology drug development and treatment, commented Anthony Hayes, CEO of Spherix. We hope that this machine learning will identify a list of genetic and expression markers that reveal when aggressive pancreatic cancer has commenced in high risk patients, which may lead to the extension of life for these patients. As a company, we are very excited to support this research.